Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Tissue Regenix Group PLC Announces dCELL Vascular Patch Shown To Be Safe And Effective


Friday, 7 Sep 2012 02:00am EDT 

Tissue Regenix Group PLC announced that the two year clinical study to evaluate the safety and performance of Tissue Regenix Group plc's ('Tissue Regenix') dCELL vascular patch supports the conclusion that it is a safe and effective device when used in vascular surgery. The study, which began in August 2009, involved 21 patients who all had a history of prior peripheral vascular disease and required surgery to remove a blood vessel blockage to restore blood flow and reduce the likelihood of further complications including possible amputation. The group of patients was typical of those with peripheral vascular disease and were suffering from a number of severe and debilitating illnesses such as diabetes. The 24 month follow up was consistent with the findings of the 12 month follow up, with post-surgery scans of the patched veins showing that it was difficult or impossible to visualise the Tissue Regenix dCELL vascular patch, which suggested it had been integrated into the patients' own vein. 

Company Quote

27.25
-0.125 -0.46%
21 Aug 2014